The Research of Medical Science Review
ISSN: 3007-1208 & 3007-1216 Volume 3, Issue 7, 2025

ROLE OF MOLECULAR DIAGNOSTICS IN EARLY DETECTION OF INFECTIOUS DISEASES

Dr. Fahad Shahzad[1], Muhammad Arjamand[*2], Anum Ahmed[3], Muhammad Hassaan Hamza[4], Aneeza Hafeez[5], Umair Anwar[6], Sadia Naz[7], Rashida Ujjan[8]

[1]*Reem Medical Center, Doha, Qatar*
[2,3,4,6]*Institute of Biological Sciences, Khwaja Fareed University of Engineering & Information Technology, Rahim Yar Khan*
[5]*Allied Health Sciences, National University of Medical Sciences, Rawalpindi*
[7]*Department of Bioinformatics, The Islamia University of Bahawalpur*
[8]*Department of Biochemistry, Shah Abdul Latif University, Khairpur*

[*2]marjamandassar283@gmail.com

DOI: https://doi.org/10.5281/zenodo.15876551

Keywords
Molecular diagnostics; Early detection; Infectious diseases; PCR; qPCR; CRISPR diagnostics; NGS; Pathogen identification; Rapid diagnosis; Disease surveillance.

Article History
Received: 08 April, 2025
Accepted: 29 June, 2025
Published: 14 July, 2025

Corresponding Author: *
Muhammad Arjamand

Abstract
Molecular diagnostics has transformed the way we detect infectious diseases by providing a way to identify pathogens accurately, quickly, and sensitively. This review highlights the fundamental molecular diagnostics technologies, including perhaps the most well-known PCR, qPCR, LAMP, NGS, and CRISPR-based platforms and provide sample applications involving the detection of a variety of infectious agents, including viruses, bacteria, parasites, and fungi. The advantages of molecular diagnostic technologies, including early diagnosis, specificity, and suitability for point-of-care testing represent a set of tools available for physicians, and represent a considerable contribution to modern medicine. Several more recent developments such as portable diagnostic technologies, digital diagnostics, and AI data analysis are evolving formats, enabling access, and adaptability across all areas of disciplines. In the future, the role of molecular diagnostics will expand further to encompass primary roles in personalized medicine, in real-time surveillance of diseases and pandemics.

INTRODUCTION

The detection of infectious disease quickly and accurately is essential for treatment, containment, and outbreak prevention. The examples of traditional techniques are culture methods, serology and microscopy. These methods are established diagnostic procedures, but have their limitations such as their low sensitivities, slow response times and having to grow the pathogen, typically in a culture medium [1]. Molecular diagnostics methods however, do offer a new paradigm allowing us to detect and identify pathogens based on their nucleic material, which has improved accuracy in diagnostics and resulted in lower time intervals between sample collection and notification of result, which benefits the management of individual patient care and public health [2].

In time molecular diagnostics has demonstrated utility for a variety of infectious diseases, for viral, bacterial, parasitic, and fungal infections. Techniques

include polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), real-time PCR (qPCR), CRISPR based detection systems, and next-generation sequencing (NGS), all of which attain high specificity and detection of very low amounts of pathogens. These methods are primarily used in more sophisticated laboratory environments, but there are newer adaptations for point-of-care (POC) diagnostics that allow for on-site decision-making, for example, in clinics, rural health care centers, and outbreak situations [3].

Regarding the increase in use and dissemination of molecular testing, new advancements are continuing to expand that potential. Examples of this include (but are by no means limited to!) the advent of portable diagnostic devices, the convergence of testing platforms with digital health services, and the implications of artificial intelligence for analytical methods. The possible applications for molecular diagnostics are significant. The previous role of molecular diagnostics was primarily as an identification system for microorganisms, but this is changing rapidly to include applications such as personalized medicine, global health surveillance augured by emerging infectious diseases, and pandemic preparedness creating a potentialized basis for future healthcare systems and models for delivery [4]. This review will examine the primary molecular methods, examples of infectious disease contexts with insight, advantages and limitations of the methods, and perspectives about promising technologies that will form the future of molecular diagnostics.

2. Molecular Diagnostic Techniques

2.1. Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) is a transformative molecular technology created by Kary Mullis in 1983, which allows scientists to amplify certain segments of DNA to generate a sufficient quantity for analysis. PCR relies upon cycles of denaturation, annealing, and extension using DNA polymerase to make as much as millions of copies of a target sequence. PCR has become integral to the early diagnosis of infectious disease because it can detect pathogens at very low levels, and because PCR has high sensitivity and specificity that allows researchers and clinicians to detect and identify pathogens even at infinitesimal quantities [5].

PCR can be used to identify infectious diseases caused by viruses, bacteria, and parasites such as HIV, tuberculosis, and malaria. Furthermore, the ability to generate pathogen-specific primers allows PCR to be used as a platform for diagnostics in clinical and research labs. Although it is a powerful platform for diagnostics, PCR is limited by the need for thermal cyclers and trained technicians in resource-limited settings. However, it is nevertheless the foundational platform that most advanced molecular diagnostics are built on [6].

2.2 Real-Time PCR (qPCR)

Real-time PCR or quantitative PCR (qPCR) is a modified form of PCR that allows the visualization of amplifying DNA in real-time format. Specifically, qPCR uses either fluorescent dye or fluorescent probes to derive quantitative measurements so that a researcher can understand the amount of DNA that is present within a sample. This characteristic is particularly helpful when a researcher is quantifying viral load or bacterial concentration in clinical specimens. The additional capabilities of real-time PCR technology provide qualitative and quantitative vantage points, which can be important when monitoring the advancement of a disease or effects of treatment interventions [7].

qPCR is frequently used to detect infectious agents early, including SARS-CoV-2, the hepatitis viruses, and human papillomavirus. Its rapid turnaround time and its capacity to be automated make qPCR a key mechanism for high-throughput screening for public health agencies in outbreak/epidemic situations or routine diagnosis in hospitals. Clearly, although equipment and reagents can create a barrier to integrating qPCR into lower-resource settings, standardized qPCR kits can be challenging. Nonetheless, qPCR continues to be one of the most accurate and most widely applied molecular diagnostic technologies that is currently being used to make decisions at the national or international levels [8].

2.3 Loop-Mediated Isothermal Amplification (LAMP)

Loop-Mediated Isothermal Amplification (LAMP) is an effective method for rapidly amplifying DNA which is highly specific for the target sequence. LAMP

operates at a fixed temperature, making the process relatively simple and inexpensive since no thermocyclers are needed. LAMP requires a set of forward and reverse primers designed in a specific manner and a DNA polymerase with strand-displacement ability. It is able to identify target DNA in 30 - 60 min creating a large volume of amplified DNA, which can be visually detected when it creates noticeable turbidity or fluorescence making it a great method for point of care testing [9].

LAMP has become one of the most widely used and notable nucleic acid amplification methods for infectious disease diagnostics, such as malaria, dengue fever, and COVID-19, especially in under-resourced areas due its low cost, rapid turnaround time and general simplicity. In addition, the advantage of obtaining visible data from LAMP, without expensive laboratory testing add another level of suitability for field testing, on-site mobile laboratory or even rural clinic [3]. Despite LAMP with all the advantages for laboratory testing setting, LAMP demands good visibility, appropriate design and assay optimization when engineered into pilot development for poorer populations of the world. While LAMP has limitations of having complex primer design, being so sensitive to contamination if not handled from start to finish with inherent lab required practices which can inevitably lead to negative amplified results even before testing. LAMP continues to be recognized for its engagement for use within diagnostic applications that can be decentralized [10].

2.4 Nucleic Acid Sequence-Based Amplification (NASBA)

Nucleic Acid Sequence-Based Amplification (NASBA) is an isothermal method used primarily to amplify RNA targets. While NASBA and PCR are both nucleic acid amplification techniques, a major difference is that NASBA does not require the thermal cycling process. NASBA has three requisite enzymes (reverse transcriptase, RNase H, T7 RNA polymerase) that will serve to amplify the signal by creating many copies of an RNA transcript. Therefore, NASBA is a highly advantageous for the detection of RNA viruses, like HIV, influenza, SARS-CoV-2 [11].

Aside from RNA being an indicator of active virus infection (therefore, potential viable pathogen presence), NASBA has significant advantages in speed, high sensitivity, and potential real-time results faster than traditional PCR based methods, making it valuable for not only DIAGNOSTIC tests but for viral load monitoring. Although NASBA is more complex than LAMP (as there is a need to monitor more controls, like reversibility of reactions, to avoid false positives/negatives). For these reasons, NASBA is well-suited in clinical laboratories, particularly for monitoring an RNA virus or viral outbreaks [12].

2.5 CRISPR-Based Diagnostics

CRISPR-based diagnostics use the gene-editing technique CRISPR-Cas systems (Cas12 and Cas13) to detect specific nucleic acid sequences from pathogens. When the CRISPR complex binds to the target sequence, collateral cleavage is activated to a reporter molecule, causing a detectable fluorescent or colorimetric signal. This has provided new opportunities to change molecular diagnostics due to specificity with a visual readout and few equipment needs [13].

Potential applications of CRISPR diagnostics include rapid detection of SARS-CoV-2, Zika virus, and bacterial infections (i.e., Mycobacterium tuberculosis). Publications with platforms like SHERLOCK and DETECTR had sensitivity, speed, and simplicity. Assays are also customizable to a paper-strip format, which could help lower resource or field-based testing situations. CRISPR diagnostics is still emerging, but it could have a compelling scalability for low-cost, precise detection of infectious diseases [14].

3. Applications in Specific Infectious Diseases

3.1 Viral Infections (e.g., HIV, Hepatitis, COVID-19)

Molecular diagnostics using techniques like PCR and qPCR have revolutionized the detection and monitoring of viral infections, such as HIV, Hepatitis B and C, and more recently, COVID-19, as these methods allow for sensitive detection of nucleic acids indicative of the viruses even in the early stages of infection or in the absence of clinical symptoms [15]. For example, molecular diagnostics can assist in early diagnostic testing for newborns infected with HIV and in monitoring viral load in groups of patients receiving complementary antiretroviral therapy for HIV. Similarly, molecular tests for detection of hepatitis viruses are used to determine viral genotype

or other markers which are used to assist in clinical decision making, pedigree risk on possible drug resistance to the hepatitis treatment regimen [16].

The COVID-19 pandemic has an impact on health worldwide with COVID-19 being a dominant human infection worldwide. The role of molecular diagnostics, especially RT-PCR testing, has been indispensable since it became the gold standard for the detection of SARS-CoV-2 worldwide. There were new tests developed also as the CRISPR and LAMP assays that can identify active cases of SARS-CoV-2 infection and/or acute diseases. Notably, these also had the advantages of being high throughput, rapid, accurate, and portable allowing for mass screening and containment responses. Molecular testing continues to play a role as an essential tool for monitoring viral mutations, variants, and to respond effectively; all of which is important as public health planning efforts as well as continuing updates to the vaccine which may be needed due to emerging variants [17].

3.2 Bacterial Infections (e.g., Tuberculosis, MRSA)

In bacterial infections, molecular diagnostics facilitate early detection, species identification, and resistance profiling, often in a fraction of the time required for culture-based methods. For tuberculosis (TB), nucleic acid amplification tests such as GeneXpert (a PCR-based system) detect Mycobacterium tuberculosis DNA and rifampicin resistance within hours, expediting treatment initiation and limiting transmission. Similarly, qPCR is widely used to detect other bacterial pathogens like Chlamydia trachomatis and Neisseria gonorrhoeae, where rapid diagnosis is essential for treatment and control [18].

Methicillin-resistant Staphylococcus aureus (MRSA) is another example where molecular diagnostics have transformed infection control. Real-time PCR allows rapid screening of hospital patients and healthcare workers, helping prevent hospital-acquired infections. Molecular methods can also identify resistance genes such as mecA and vanA, which are crucial for tailoring antimicrobial therapy. These capabilities not only improve patient outcomes but also support antimicrobial stewardship efforts and infection control policies in healthcare settings [19].

3.3 Parasitic Infections (e.g., Malaria)

Parasitic infections, especially malaria, can greatly benefit from molecular diagnostics, especially in areas where microscopy and antigen-based methods are limited. PCR-based methods can identify very low levels of Plasmodium DNA, and subsequently, the diagnosis of submicroscopic infections and mixed infections. This is vital because asymptomatic carriers can still help to sustain malaria transmission in endemic areas. Molecular testing provides further support in malaria elimination scenarios by allowing for sensitive screening during active surveillance programs [20].

LAMP assays are particularly meaningful in malaria diagnostics, especially in non-laboratory field conditions, and these assays have been proven to provide a rapid and simplified process with minimal equipment. The ability to detect all human Plasmodium spp. on-site is a potential attractive option to replace methods that are labor-intensive and long. Also, molecular diagnostics are being used more often to monitor drug resistance trends in malaria parasites which could reinforce the links between inconsistent treatment responses to Dutchmalaria control program recommendations and to measure treatment success rates within national malaria control programs [21].

3.4 Fungal Infections (e.g., Candidiasis)

Fungal infections, including candidiasis, can be hard to diagnose, due to slow to grow fungal cultures and often non-specific clinical presentations. Molecular methods comprise excellent rapid and specific alternatives based on identification of fungal DNA directly from clinical specimens. PCR assays can identify both C. albicans and non-albicans Candida species, which is vital for appropriate therapeutic efficacy based on potential differential clinical responses. There is reassurance with specificity to ensure improved patient management and better clinical outcomes [22].

For invasive fungal infections in immunocompromised patients, time is essential. In addition, fungal detection can be facilitated by quantitative measures. qPCR and DNA microarrays are rapid detection methods that have successfully identified low fungal loads in clinical specimens; for example, blood or tissue harboring fungal pathogens

such as Aspergillus and Cryptococcus. When new rapid tests provide rapid results to facilitate early therapeutic decisions, clinicians understand that a fungal infection can do a good deal of harm in spelling that possibility out in less than 24 hours of collection. Also, with antifungal resistance now being predictable in some species, molecular diagnostics can increasingly targets the mutations that drive antifungal resistance [23].

4. Advantages of Molecular Diagnostics

4.1 High Sensitivity and Specificity

Molecular diagnostics provide a level of sensitivity and specificity that has not been available from routine diagnostic tests in history. With the capability of identifying tiny amounts of nucleic acid, molecular diagnostics even has the ability to detect an infectious pathogen early in an infection or at a time when the patient's pathogen burden is low. The level of sensitivity available will be of additional importance when diagnosing a latent or subclinical infection. This sensitivity will allow for better and earlier clinical treatment options [24].

Molecular diagnostics allow for increased specificity utilizing unique genetic sequences of the infectious agent, and limited potential for cross-reactivity and false positives as seen with serological diagnostics. The availability of specificity allows for an accurate determination of pathogen subtypes and pathogen genotypes which aids in epidemiologic capacity building and personalized treatment for the patient [25].

4.2 Rapid Turnaround Time

The ability to get results swiftly for several microorganisms is one of the biggest advantages of molecular testing, as results from molecular methods can be ready within hours, while culture methods can take days to weeks to identify a pathogen. The turnaround time is more critical for acute or life threatening infections, as a better diagnosis can improve patient outcomes [26].

Turnaround time is also essential for controlling infections while hospitalized in healthcare environments. If you are able to obtain results quickly using molecular methods, facilities can isolate infected patients, initiate targeted therapy, and decrease the rate of transmission. This has been truly beneficial during outbreaks, such as the coronavirus outbreak, where it has meant being able to diagnose patients in hours rather than days was a huge advantage to public safety and containment [27].

4.3 Early and Accurate Diagnosis

Molecular diagnostics provide an important advantage in early diagnosis by allowing the detection of an infection potentially before clinical symptoms have been fully expressed. It is especially critical for diseases like HIV, TB, and viral hepatitis to diagnose infection as early as possible because late diagnosis can lead to potentially irreversible health damages or transmission. Timely diagnosis allows for earlier initiation of treatment, which can often be more effective and less costly [28].

Another important advantage of molecular diagnostics is the accuracy of clinical diagnosis. By focusing on the genetic material of the pathogen itself, molecular methods do not rely on often ambiguous symptom-based diagnosis or serological tests. Obtaining an accurate identification of the infectious agent assures that patients will obtain the correct treatment to avoid complications and manage them effectively [29].

4.4 Potential for Point-of-Care Use

The emergence of simplified and portable molecular diagnostics, such as LAMP and CRISPR-based assays, is establishing a foundation for the further adoption of point-of-care (POC) testing. These techniques are being designed for use in the field, in locations with minimal laboratory support and where the infrastructure for laboratories is minimal or lacking. The use of these techniques allows frontline healthcare workers to make real-time decisions for patient care in areas with poor or no access to laboratory support [30].

POC molecular diagnostics allow testing to take place in rural and underserved populations. These POC molecular diagnostics contribute to more widespread access to testing, potentially leading to earlier and decentralized detection, as well as enhanced disease surveillance and management of outbreaks. The design, accessibility, and affordability of POC molecular diagnostics will help facilitate the re-imagining of diagnostic services worldwide [31].

5. Recent Advances and Innovations

5.1 Portable and Point-of-Care Devices

In recent years, there have been small, portable molecular diagnostic devices that deliver testing right at the patient's location. These point-of-care (POC) systems include handheld PCR and isothermal amplification platforms that were designed to operate without a complex infrastructure. With techniques including loop-mediated isothermal amplification (LAMP), microfluidic chips, and CRISPR diagnostics, the development of low-cost and simple devices has also accelerated that produce timely and accurate results, and significantly, outside of a laboratory [32].

The arrival of these portable devices is impacting diagnostics in resource-limited, emergency, and underserved settings where access to central laboratories may be limited. Their hand-held simplicity, low sample volume, and rapid turnaround make these POC devices appealing for disease screening, outbreak management, and routine surveillance. As seen during the COVID-19 pandemic, the rapid promotion of these tools will show the potential for large-scale public health interventions and immediate integration into daily clinical practice [33].

5.2 Integration with Digital Health Platforms

Digital health platforms are changing how diagnostic information is recorded, distributed and interpreted as they are connected to molecular diagnostics. Now cloud-connected diagnostic devices can transmit test results to a central database or a healthcare provider right away. This integration improves patient monitoring, remote diagnosis, and access to accurate data to inform public health actions [34].

These advances are particularly important for disease surveillance and outbreak management. By connecting diagnostic data with geographical or demographic data, digital platforms can aid in tracking the course of infectious disease outbreaks and inform targeted public health responses. The combination of mobile health applications and of telemedicine platforms with diagnostic devices is making healthcare delivery possible to underserved groups, consequently improving health equity and clinical outcomes and assuring tailored health care and services [35].

5.3 AI and Machine Learning in Molecular Diagnostics

Applications of artificial intelligence (AI) and machine learning (ML) in molecular diagnostics are enhancing the speed, accuracy and predictive nature of results. For instance, pathogen or agent identification via PCR, next generation sequencing (NGS) or microarray has advanced to the point where it may be difficult for the human eye to discern some patterns or aberrations in the resulting complex data sets. AI algorithms can offer assistance in pathogen identification and mutation genotyping, and support prediction of the likelihood of antimicrobial resistance, thus supporting greater precision in personalized medicine [36].

There is an explicit trend in research and practice in which ML approaches are specifically being employed to refine assay design and support automation of data interpretation of findings, or optimizing a personalized diagnostic pathway according to patient and patient outcome. ML algorithms are being used to assist in genomic surveillance to identify new viral strains, and possibly even predict outbreaks of disease based on molecular patterns and trends. The integration of AI to a diagnostic pathway can reduce human weighted errors, reduce time for results, and ultimately contribute better clinical decision making resulting in more efficient and future-ready diagnostics [37].

6. Future Prospects

6.1 Personalized Medicine and Targeted Therapies

Molecular diagnostics is poised to fully transform personalized medicine via accurate identification of infectious agents and personal genetic information. Clinicians can create personalized treatment regimens using genomic and transcriptomic data, including the pathogen, its genetic features, and the host's genetic makeup. This approach will help clinicians optimize drug choices, while minimizing adverse drug reactions and maximizing clinical response outcomes especially for chronic viral infections (e.g., HIV and hepatitis) [38].

As insights improve into host-pathogen interactions, and biomarkers are identified for disease progression and drug resistance, molecular diagnostics will advance our ability to use targeted therapies, dose adjust based on genetics, and real time monitoring of

clinical response. Eventually, personalized medicine will revolutionize our approach to infectious disease (and possibly all medical disciplines) from current practice of standardizing treatment protocols to a patient-centered, individualized care [39].

6.2 Global Disease Surveillance

The potential of molecular diagnostics to surveil and detect infectious diseases globally in real-time is very exciting. Public health departments are increasingly able to use high-throughput techniques such as next-generation sequencing (NGS) to rapidly identify emerging pathogens, track the evolution of pathogens and respond appropriately before transmissible disease outbreaks can spread. This timely response capability will be vitally important for managing zoonotic spillovers, novel viral threats, and antimicrobial resistance [40].

With the advancement of mobile molecular diagnostic technologies and the implementation of integrated data reporting systems, all countries from the most developed to the least developed will have access to real-time data reporting. As increasingly sophisticated testing platforms become implemented and integrated with global health networks around the world, timely consensus actions by the global community will occur sooner and with more coordinated responses to infectious disease threats. Ultimately there is little doubt molecular diagnostics will play a pivotal role in developing and implementing a more active, objective, and data-based global health surveillance system [41].

6.3 Pandemic Preparedness and Rapid Response

The COVID-19 pandemic brought to light the necessity of fast, accurate, and scalable platforms for diagnostic testing to manage a public health emergency. Molecular diagnostics became a key resource to identify and isolate cases, tracing genetic mutations, and informing treatment plans. Future pandemic preparedness planning will continue to rely on putting molecular diagnostics in place quickly and widely throughout the health system [42].

The integration of formal assay development initiatives, mobile laboratory testing units, and decentralized laboratory design and networks improve ready access to systems for future pandemics. We also need an investment in our molecular diagnostic infrastructure; training and innovative models of care to make sure those health systems can identify new pathogens early, scale up efficient mass screening, and adapt diagnostics to evolving pathogens. These health technologies will help save lives and alleviate the socio-economic consequences of global health emergencies [4].

Conclusion

Advancements in molecular d iagnostics have become a vital component shaping the future of worldwide health; it is at the head of modern capabilities for detecting, managing and treating infectious disease because of the unmatched accuracy, speed, and flexibility these techniques provide. With molecular diagnostic techniques such as PCR, qPCR, LAMP, and NGS, clinicians, public health experts, and infection specialists can identify infections and implement a plan of action with more robustness and efficiency than ever before. The ability to utilize these new diagnostic tools across multiple infectious diseases has had major effects resulting in detection and treatment earlier and better patient outcomes. There are continual rapid advancements in the miniaturization of technologies and the integration of AI and digital health platforms to provide practical utility of molecular diagnosis across both high resource and low resource settings. It is anticipated that molecular diagnostics will occupy broader roles in personalized health care, global surveillance, and pandemic response, and in this capacity will remain a crucial aspect of global health going forward.

References

1 Meckawy, R., et al., *Effectiveness of early warning systems in the detection of infectious diseases outbreaks: a systematic review.* BMC public health, 2022. **22**(1): p. 2216.

2. Birkhead, G.S., M. Klompas, and N.R. Shah, *Uses of electronic health records for public health surveillance to advance public health.* Annual review of public health, 2015. **36**(1): p. 345-359.

3. Islam, M.M. and D. Koirala, *Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses.* Analytica chimica acta, 2022. **1209**: p. 339338.

4. Tenover, F.C., *The role for rapid molecular diagnostic tests for infectious diseases in precision medicine.* Expert Review of Precision Medicine and Drug Development, 2018. **3**(1): p. 69-77.
5. Tayyeb, A. and Z. Basit, *Polymerase Chain Reaction*, in *Genetic Engineering*. 2023, Apple Academic Press. p. 119-146.
6. Zauli, D.A.G., *PCR and infectious diseases.* Synthetic Biology-New Interdisciplinary Science, 2019: p. 137-145.
7. Jyothy, A., S.T. Sabu, and S.S. Dharan, *REAL-TIME PCR OR QUANTITATIVE PCR (QPCR)–A REVOLUTION IN MODERN SCIENCE.* World Journal of Pharmaceutical Research, 2020. **9**(11): p. 249-264.
8. Jian, Y. and M. Li, *A narrative review of single-nucleotide polymorphism detection methods and their application in studies of Staphylococcus aureus.* Journal of Bio-X research, 2021. **4**(01): p. 1-9.
9. Wong, Y.P., et al., *Loop-mediated isothermal amplification (LAMP): a versatile technique for detection of micro-organisms.* Journal of applied microbiology, 2018. **124**(3): p. 626-643.
10. Moehling, T.J., et al., *LAMP diagnostics at the point-of-care: emerging trends and perspectives for the developer community.* Expert Review of Molecular Diagnostics, 2021. **21**(1): p. 43-61.
11. Bukasov, R., D. Dossym, and O. Filchakova, *Detection of RNA viruses from influenza and HIV to Ebola and SARS-CoV-2: a review.* Analytical Methods, 2021. **13**(1): p. 34-55.
12. Reta, D.H., et al., *Molecular and immunological diagnostic techniques of medical viruses.* International Journal of Microbiology, 2020. **2020**(1): p. 8832728.
13. Li, P., et al., *Applications of the CRISPR-Cas system for infectious disease diagnostics.* Expert Review of Molecular Diagnostics, 2021. **21**(7): p. 723-732.
14. Rahman, M.R., et al., *CRISPR-Based Programmable Nucleic Acid-Binding Protein Technology Can Specifically Detect Fatal Tropical Disease-Causing Pathogens.* Journal of Tropical Medicine, 2022. **2022**(1): p. 5390685.
15. Kaushik, R., et al., *Introduction to Molecular Diagnostics and Viral Diseases*, in *Molecular Diagnostics for Viral Diseases*. 2025, Springer. p. 1-28.
16. Yang, T.-H., et al., *Genetic susceptibility to hepatocellular carcinoma in patients with chronic hepatitis virus infection.* Viruses, 2023. **15**(2): p. 559.
17. Tsang, N.N.Y., et al., *Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.* The Lancet Infectious Diseases, 2021. **21**(9): p. 1233-1245.
18. Tsalik, E.L., R.A. Bonomo, and V.G. Fowler Jr, *New molecular diagnostic approaches to bacterial infections and antibacterial resistance.* Annual review of medicine, 2018. **69**(1): p. 379-394.
19. Lakhundi, S. and K. Zhang, *Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology.* Clinical microbiology reviews, 2018. **31**(4): p. 10.1128/cmr. 00020-18.
20. Nyenke, C.U., *EMERGING TECHNIQUES IN MALARIA DIAGNOSIS.* Issues on Health Science, 2024. **1**: p. 1-16.
21. Su, X.-z., et al., *Plasmodium genomics and genetics: new insights into malaria pathogenesis, drug resistance, epidemiology, and evolution.* Clinical microbiology reviews, 2019. **32**(4): p. 10.1128/cmr. 00019-19.
22. Sedik, S., et al., *Diagnosing fungal infections in clinical practice: A narrative review.* Expert Review of Anti-infective Therapy, 2024. **22**(11): p. 935-949.
23. White, P.L., et al., *Nucleic acid tools for invasive fungal disease diagnosis.* Current Fungal Infection Reports, 2020. **14**: p. 76-88.
24. Sokolenko, A.P. and E.N. Imyanitov, *Molecular diagnostics in clinical oncology.* Frontiers in molecular biosciences, 2018. **5**: p. 76.
25. Wang, R.C. and Z. Wang, *Precision medicine: disease subtyping and tailored treatment.* Cancers, 2023. **15**(15): p. 3837.
26. Law, J.W.-F., et al., *Rapid methods for the detection of foodborne bacterial pathogens: principles, applications, advantages and limitations.* Frontiers in microbiology, 2015. **5**: p. 770.
27. Salian, V.S., et al., *COVID-19 transmission, current treatment, and future therapeutic strategies.* Molecular pharmaceutics, 2021. **18**(3): p. 754-771.

28. Schmitz, J.E., et al., *Forty years of molecular diagnostics for infectious diseases.* Journal of clinical microbiology, 2022. **60**(10): p. e02446-21.
29. Vaca, D.J., et al., *Contemporary diagnostics for medically relevant fastidious microorganisms belonging to the genera Anaplasma, Bartonella, Coxiella, Orientia and Rickettsia.* FEMS microbiology reviews, 2022. **46**(4): p. fuac013.
30. Zu, Y., H. Chang, and Z. Cui, *Molecular point-of-care testing technologies: current status and challenges.* Nexus, 2025.
31. Chakraborty, S., *Democratizing nucleic acid-based molecular diagnostic tests for infectious diseases at resource-limited settings–from point of care to extreme point of care.* Sensors & Diagnostics, 2024. **3**(4): p. 536-561.
32. Botella, J.R., *Point-of-care DNA amplification for disease diagnosis and management.* Annual Review of Phytopathology, 2022. **60**(1): p. 1-20.
33. Dima, K., *Point of care testing (POCT) present and future.* There is no corresponding record for this reference, 2021.
34. Neumaier, M., *Diagnostics 4.0: the medical laboratory in digital health.* Clinical Chemistry and Laboratory Medicine (CCLM), 2019. **57**(3): p. 343-348.
35. Arefin, S., *Health Equity and Solutions in the United States Healthcare System.* Integrated Journal of Science and Technology, 2024. **1**(5): p. 1-9.
36. Nichols, J.A., H.W. Herbert Chan, and M.A. Baker, *Machine learning: applications of artificial intelligence to imaging and diagnosis.* Biophysical reviews, 2019. **11**: p. 111-118.
37. Vashisht, V., et al., *Genomics for emerging pathogen identification and monitoring: Prospects and obstacles.* BioMedInformatics, 2023. **3**(4): p. 1145-1177.
38. Kwok, A.J., A. Mentzer, and J.C. Knight, *Host genetics and infectious disease: new tools, insights and translational opportunities.* Nature Reviews Genetics, 2021. **22**(3): p. 137-153.
39. Afzal, S., et al., *Breast cancer; discovery of novel diagnostic biomarkers, drug resistance, and therapeutic implications.* Frontiers in molecular biosciences, 2022. **9**: p. 783450.
40. Li, N., et al., *High-throughput metagenomics for identification of pathogens in the clinical settings.* Small methods, 2021. **5**(1): p. 2000792.
41. Bartels, M., et al., *Evolving and Improving the Sustainability of Molecular Tumor Boards: The Value and Challenges.* Cancers, 2024. **16**(16): p. 2888.
42. Dwivedi, S., et al., *Diseases and molecular diagnostics: a step closer to precision medicine.* Indian Journal of Clinical Biochemistry, 2017. **32**: p. 374-398.